{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:57Z","timestamp":1792787817742,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Headache Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s10194-017-0807-1","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T08:18:54Z","timestamp":1506327534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":268,"title":["Blocking CGRP in migraine patients \u2013 a review of pros and cons"],"prefix":"10.1186","volume":"18","author":[{"name":"On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-9841","authenticated-orcid":false,"given":"Marie","family":"Deen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvige","family":"Correnti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Kelderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Papetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Rubio-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Edvinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Maassen Van Den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"807_CR1","first-page":"2","volume":"2","author":"L Edvinsson","year":"1985","unstructured":"Edvinsson L (1985) Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci 2:2\u20137","journal-title":"Trends Neurosci"},{"key":"807_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48\u201356. doi: 10.1002\/ana.410330109","journal-title":"Ann Neurol"},{"key":"807_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1526-4610.1994.hed3407394.x","volume":"34","author":"PJ Goadsby","year":"1994","unstructured":"Goadsby PJ, Edvinsson L (1994) Peripheral and central Trigeminovascular activation in cat is blocked by the serotonin (5HT)-I D receptor agonist 311C90. Headache J Head Face Pain 34:394\u2013399. doi: 10.1111\/j.1526-4610.1994.hed3407394.x","journal-title":"Headache J Head Face Pain"},{"key":"807_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB et al (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54\u201361. doi: 10.1046\/j.1468-2982.2002.00310.x","journal-title":"Cephalalgia"},{"key":"807_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0304-3940(85)90296-4","volume":"62","author":"R Uddman","year":"1985","unstructured":"Uddman R, Edvinsson L, Ekman R et al (1985) Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 62:131\u2013136. doi: 10.1016\/0304-3940(85)90296-4","journal-title":"Neurosci Lett"},{"key":"807_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcp.12618","volume":"80","author":"L Edvinsson","year":"2015","unstructured":"Edvinsson L (2015) CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol 80:193\u2013199. doi: 10.1111\/bcp.12618","journal-title":"Br J Clin Pharmacol"},{"key":"807_CR7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jpain.2013.03.010","volume":"14","author":"S Eftekhari","year":"2013","unstructured":"Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14:1289\u20131303. https:\/\/doi.org\/10.1016\/j.jpain.2013.03.010","journal-title":"J Pain"},{"key":"807_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1756285610388343","volume":"3","author":"S Eftekhari","year":"2010","unstructured":"Eftekhari S, Edvinsson L (2010) Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord 3:369\u2013378. https:\/\/doi.org\/10.1177\/1756285610388343","journal-title":"Ther Adv Neurol Disord"},{"key":"807_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","volume":"37","author":"A MaassenVanDenBrink","year":"2016","unstructured":"MaassenVanDenBrink A, Meijer J, Villal\u00f3n CM, Ferrari MD (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37:779\u2013788. https:\/\/doi.org\/10.1016\/j.tips.2016.06.002","journal-title":"Trends Pharmacol Sci"},{"key":"807_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-017-0741-2","volume":"18","author":"WS Schou","year":"2017","unstructured":"Schou WS, Ashina S, Amin FM et al (2017) Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain 18:34. doi: 10.1186\/s10194-017-0741-2","journal-title":"J Headache Pain"},{"key":"807_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(10)60323-6","volume":"376","author":"L Edvinsson","year":"2010","unstructured":"Edvinsson L, Linde M (2010) New drugs in migraine treatment and prophylaxis: Telcagepant and topiramate. Lancet 376:645\u2013655. doi: 10.1016\/S0140-6736(10)60323-6","journal-title":"Lancet"},{"key":"807_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie S-J et al (2014) Calcitonin gene-related peptide: physiology and Pathophysiology. Physiol Rev 94:1099\u20131142. doi: 10.1152\/physrev.00034.2013","journal-title":"Physiol Rev"},{"key":"807_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/sj.bjp.0703110","volume":"129","author":"H Doods","year":"2000","unstructured":"Doods H, Hallermayer G, Wu D et al (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129:420\u2013423. doi: 10.1038\/sj.bjp.0703110","journal-title":"Br J Pharmacol"},{"key":"807_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1517\/13543784.2015.960921","volume":"24","author":"L V\u00e9csei","year":"2015","unstructured":"V\u00e9csei L, Szok D, Cs\u00e1ti A, Tajti J (2015) CGRP antagonists and antibodies for the treatment of migraine. Expert Opin Investig Drugs 24:31\u201341. doi: 10.1517\/13543784.2015.960921","journal-title":"Expert Opin Investig Drugs"},{"key":"807_CR15","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/head.12179","volume":"53","author":"ME Bigal","year":"2013","unstructured":"Bigal ME, Walter S, Rapoport AM (2013) Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 53:1230\u20131244. doi: 10.1111\/head.12179","journal-title":"Headache"},{"key":"807_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejphar.2007.04.004","volume":"567","author":"L Juhl","year":"2007","unstructured":"Juhl L, Edvinsson L, Olesen J, Jansen-Olesen I (2007) Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur J Pharmacol 567:117\u2013124. doi: 10.1016\/j.ejphar.2007.04.004","journal-title":"Eur J Pharmacol"},{"key":"807_CR17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.bjp.0707134","volume":"150","author":"L Edvinsson","year":"2007","unstructured":"Edvinsson L, Nilsson E, Jansen-Olesen I (2007) Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. BrJPharmacol 150:633\u2013640. doi: 10.1038\/sj.bjp.0707134","journal-title":"BrJPharmacol"},{"key":"807_CR18","doi-asserted-by":"crossref","unstructured":"Olesen J, Diener H, Husstedt IW, et al (2004) Calcitonin gene\u2013related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. Society 1104\u20131110","DOI":"10.1056\/NEJMoa030505"},{"key":"807_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1526-4610.2010.01799.x","volume":"51","author":"KM Connor","year":"2011","unstructured":"Connor KM, Aurora SK, Loeys T et al (2011) Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 51:73\u201384. doi: 10.1111\/j.1526-4610.2010.01799.x","journal-title":"Headache"},{"key":"807_CR20","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1212\/WNL.0b013e3181b87942","volume":"73","author":"KM Connor","year":"2009","unstructured":"Connor KM, Shapiro RE, Diener H-C et al (2009) Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73:970\u2013977","journal-title":"Neurology"},{"key":"807_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"H-C Diener","year":"2011","unstructured":"Diener H-C, Barbanti P, Dahl\u00f6f C et al (2011) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31:573\u2013584. doi: 10.1177\/0333102410388435","journal-title":"Cephalalgia"},{"key":"807_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/0333102411398399","volume":"31","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, Aurora SK, Dodick DW et al (2011) Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31:712\u2013722. doi: 10.1177\/0333102411398399","journal-title":"Cephalalgia"},{"key":"807_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1526-4610.2011.01860.x","volume":"51","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, Martin V, Lipton RB et al (2011) Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Headache 51:533\u2013543. doi: 10.1111\/j.1526-4610.2011.01860.x","journal-title":"Headache"},{"key":"807_CR24","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1177\/0333102410370878","volume":"30","author":"AP Ho","year":"2010","unstructured":"Ho AP, Dahl\u00f6f CG, Silberstein SD et al (2010) Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 30:1443\u20131457. doi: 10.1177\/0333102410370878","journal-title":"Cephalalgia"},{"key":"807_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","volume":"83","author":"TW Ho","year":"2014","unstructured":"Ho TW, Connor KM, Zhang Y et al (2014) Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 83:958\u2013966. doi: 10.1212\/WNL.0000000000000771","journal-title":"Neurology"},{"key":"807_CR26","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115\u20132123. doi: 10.1016\/S0140-6736(08)61626-8","journal-title":"Lancet"},{"key":"807_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1526-4610.2011.02052.x","volume":"52","author":"TW Ho","year":"2012","unstructured":"Ho TW, Ho AP, Chaitman BR et al (2012) Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache 52:224\u2013235. doi: 10.1111\/j.1526-4610.2011.02052.x","journal-title":"Headache"},{"key":"807_CR28","doi-asserted-by":"publisher","unstructured":"Ho TW, Ho AP, Ge Y (Joy), et al (2016) Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia 36:148\u2013161. doi: 10.1177\/0333102415584308","DOI":"10.1177\/0333102415584308"},{"key":"807_CR29","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1212\/01.WNL.0000286940.29755.61","volume":"70","author":"TW Ho","year":"2008","unstructured":"Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-3207, in the acute treatment of migraine. Neurology 70:1304\u20131312. doi: 10.1177\/0333102411398399","journal-title":"Neurology"},{"key":"807_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D et al (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114\u2013125. doi: 10.1177\/0333102413500727","journal-title":"Cephalalgia"},{"key":"807_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S et al (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382\u2013390. doi: 10.1016\/S1474-4422(16)00019-3","journal-title":"Lancet Neurol"},{"key":"807_CR32","doi-asserted-by":"publisher","unstructured":"Tepper S, Ashina M, Reuter U, et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. doi: 10.1016\/S1474-4422(17)30083-2","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"807_CR33","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"T Voss","year":"2016","unstructured":"Voss T, Lipton RB, Dodick DW et al (2016) A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36:887\u2013898. doi: 10.1177\/0333102416653233","journal-title":"Cephalalgia"},{"key":"807_CR34","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD et al (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100\u20131107. doi: 10.1016\/S1474-4422(14)70209-1","journal-title":"Lancet Neurol"},{"key":"807_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Spierings ELH et al (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885\u2013892. doi: 10.1016\/S1474-4422(14)70128-0","journal-title":"Lancet Neurol"},{"key":"807_CR36","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Dodick DW, Rapoport AM et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081\u20131090. doi: 10.1016\/S1474-4422(15)00249-5","journal-title":"Lancet Neurol"},{"key":"807_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091\u20131100. doi: 10.1016\/S1474-4422(15)00245-8","journal-title":"Lancet Neurol"},{"key":"807_CR38","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2147\/NDT.S3497","volume":"4","author":"D D\u2019Amico","year":"2008","unstructured":"D\u2019Amico D, Tepper SJ (2008) Prophylaxis of migraine: General principles and patient acceptance. Neuropsychiatr Dis Treat 4:1155\u20131167. doi: 10.2147\/NDT.S3497 .","journal-title":"Neuropsychiatr Dis Treat"},{"key":"807_CR39","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, et al. (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology 78:1337\u201345. doi: 10.1212\/WNL.0b013e3182535d20 .","journal-title":"Neurology"},{"key":"807_CR40","unstructured":"Lilly\u2019s Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS (NYSE:LLY). https:\/\/investor.lilly.com\/releasedetail.cfm?releaseid=1029791 . Accessed 21 Aug 2017"},{"key":"807_CR41","unstructured":"Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine (NASDAQ:ALDR). http:\/\/investor.alderbio.com\/releasedetail.cfm?releaseid=1031418 . Accessed 21 Aug 2017"},{"key":"807_CR42","unstructured":"Teva\u2019s Fremanezumab Meets all Primary and Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention. http:\/\/www.tevapharm.com\/news\/teva_s_fremanezumab_meets_all_primary_secondary_endpoints_across_both_monthly_and_quarterly_dosing_regimens_in_phase_iii_study_in_episodic_migraine_prevention_06_17.aspx . Accessed 21 Aug 2017"},{"key":"807_CR43","unstructured":"Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine | Novartis. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-phase-iii-study-shows-amg-334-significantly-reduces-monthly . Accessed 21 Aug 2017"},{"key":"807_CR44","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jama.291.8.965","volume":"291","author":"J Brandes","year":"2004","unstructured":"Brandes J, Saper J, Diamond M et al (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291:965\u2013973. doi: 10.1592\/phco.26.3.375","journal-title":"JAMA"},{"key":"807_CR45","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00415-004-0464-6","volume":"251","author":"H-C Diener","year":"2004","unstructured":"Diener H-C, Tfelt-Hansen P, Dahl\u00f6f C et al (2004) Topiramate in migraine prophylaxis results from a placebo-controlled trial with propranolol as an active control. J Neurol 251:943\u2013950. doi: 10.1007\/s10072-005-0425-6","journal-title":"J Neurol"},{"key":"807_CR46","doi-asserted-by":"publisher","unstructured":"Silberstein SD, Standnes B, Kangasneimi P, et al (2004) Topiramate in migraine prevention. Arch Neurol 61:490\u2013495. doi: 10.1001\/archneur.61.4.490","DOI":"10.1001\/archneur.61.4.490"},{"key":"807_CR47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","volume":"47","author":"SD Silberstein","year":"2007","unstructured":"Silberstein SD, Lipton RB, Dodick DW et al (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47:170\u2013180. doi: 10.1111\/j.1526-4610.2006.00684.x","journal-title":"Headache"},{"key":"807_CR48","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"HC Diener","year":"2007","unstructured":"Diener HC, Bussone G, Van Oene JC et al (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814\u2013823. doi: 10.1111\/j.1468-2982.2007.01326.x","journal-title":"Cephalalgia"},{"key":"807_CR49","unstructured":"Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine (NYSE:LLY). https:\/\/investor.lilly.com\/releasedetail.cfm?releaseid=1026201 . Accessed 21 Aug 2017."},{"key":"807_CR50","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548\u2013558. doi: 10.1038\/clpt.2008.170","journal-title":"Clin Pharmacol Ther"},{"key":"807_CR51","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/bcp.12591","volume":"79","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Walter S, Rapoport AM (2015) Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol 79:886\u2013895. doi: 10.1111\/bcp.12591","journal-title":"Br J Clin Pharmacol"},{"key":"807_CR52","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2016","unstructured":"Iyengar S, Ossipov MH, Johnson KW (2016) The role of CGRP in peripheral and central pain mechanisms including migraine. Pain 158:543\u2013559. doi: 10.1097\/j.pain.0000000000000831","journal-title":"Pain"},{"key":"807_CR53","first-page":"136","volume":"29","author":"C Sur","year":"2009","unstructured":"Sur C, Hargreaves RJ, Bell IM et al (2009) CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer. Cephalalgia 29:136\u2013137","journal-title":"Cephalalgia"},{"key":"807_CR54","doi-asserted-by":"publisher","unstructured":"Uddman R, Edvinsson L, Ekblad E et al (1986) Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 15:1\u201323. doi: 10.1016\/0167-0115(86)90071-6","DOI":"10.1016\/0167-0115(86)90071-6"},{"key":"807_CR55","doi-asserted-by":"crossref","unstructured":"Wimalawansa J, MacIntyre I (1988) Calcitonin gene-related peptide and its specific binding sites in the cardiovascular system of rat. Int J Cardiol 20:29\u201337","DOI":"10.1016\/0167-5273(88)90313-0"},{"key":"807_CR56","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0008-6363(96)88520-8","volume":"29","author":"OS Opgaard","year":"1995","unstructured":"Opgaard OS, Gulbenkian S, Bergdahl A et al (1995) Innervation of human epicardial coronary veins: immunohistochemistry and vasomotility. Cardiovasc Res 29:463\u2013468","journal-title":"Cardiovasc Res"},{"key":"807_CR57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/08037050600996586","volume":"15","author":"IH Lindstedt","year":"2006","unstructured":"Lindstedt IH, Edvinsson M-L, Edvinsson L (2006) Reduced responsiveness of cutaneous microcirculation in essential hypertension--a pilot study. Blood Press 15:275\u2013280. doi: 10.1080\/08037050600996586","journal-title":"Blood Press"},{"key":"807_CR58","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1073\/pnas.83.15.5731","volume":"83","author":"J McCulloch","year":"1986","unstructured":"McCulloch J, Uddman R, Kingman TA, Edvinsson L (1986) Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A 83:5731\u20135735. doi: 10.1073\/pnas.83.15.5731","journal-title":"Proc Natl Acad Sci U S A"},{"key":"807_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0165-1838(98)00033-2","volume":"70","author":"L Edvinsson","year":"1998","unstructured":"Edvinsson L, Uddman R, Mulder H (1998) Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J Aut Nerv Syst 70:15\u201322","journal-title":"J Aut Nerv Syst"},{"key":"807_CR60","first-page":"H1571","volume":"279","author":"IM Keith","year":"2000","unstructured":"Keith IM, Tjen AL, Kraiczi H, Ekman R (2000) Three-week neonatal hypoxia reduces blood CGRP and causes persistent pulmonary hypertension in rats. AmJPhysiolHeart CircPhysiol 279:H1571\u2013H1578","journal-title":"AmJPhysiolHeart CircPhysiol"},{"key":"807_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-014-0524-1","volume":"16","author":"S Sacco","year":"2014","unstructured":"Sacco S, Kurth T (2014) Migraine and the risk for stroke and cardiovascular disease. Curr Cardiol Rep 16:1\u20137. doi: 10.1007\/s11886-014-0524-1","journal-title":"Curr Cardiol Rep"},{"key":"807_CR62","doi-asserted-by":"publisher","first-page":"i2610","DOI":"10.1136\/bmj.i2610","volume":"253","author":"T Kurth","year":"2016","unstructured":"Kurth T, Winter AC, Eliassen AH et al (2016) Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 253:i2610. doi: 10.1136\/bmj.i2610","journal-title":"BMJ"},{"key":"807_CR63","doi-asserted-by":"publisher","unstructured":"Salmona M, Damaj Mi, Marubio Lm, et al (2001) Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice. Nat Neurosci 4:357\u2013358. doi: 10.1100\/tsw.2001.439","DOI":"10.1100\/tsw.2001.439"},{"key":"807_CR64","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0304-3959(00)00378-X","volume":"89","author":"L Zhang","year":"2001","unstructured":"Zhang L, Hoff AO, Wimalawansa SJ et al (2001) Arthritic calcitonin\/\u03b1 calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain 89:265\u2013273. doi: 10.1016\/S0304-3959(00)00378-X","journal-title":"Pain"},{"key":"807_CR65","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.joca.2014.01.009","volume":"22","author":"RJ Benschop","year":"2014","unstructured":"Benschop RJ, Collins EC, Darling RJ et al (2014) Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthr Cartil 22:578\u2013585. doi: 10.1016\/j.joca.2014.01.009","journal-title":"Osteoarthr Cartil"},{"key":"807_CR66","doi-asserted-by":"publisher","first-page":"B354","DOI":"10.1093\/gerona\/51A.5.B354","volume":"51A","author":"Z Khalil","year":"1996","unstructured":"Khalil Z, Helme R (1996) Sensory peptides as Neuromodulators of wound healing in aged rats. J Gerontol Ser A Biol Sci Med Sci 51A:B354\u2013B361. doi: 10.1093\/gerona\/51A.5.B354","journal-title":"J Gerontol Ser A Biol Sci Med Sci"},{"key":"807_CR67","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/jid.2012.464","volume":"133","author":"D Roggenkamp","year":"2013","unstructured":"Roggenkamp D, K\u00f6pnick S, St\u00e4b F et al (2013) Epidermal nerve fibers modulate Keratinocyte growth via Neuropeptide signaling in an innervated skin model. J Invest Dermatol 133:1620\u20131628. doi: 10.1038\/jid.2012.464","journal-title":"J Invest Dermatol"},{"key":"807_CR68","doi-asserted-by":"publisher","first-page":"H431","DOI":"10.1152\/ajpheart.00466.2010","volume":"300","author":"T Mishima","year":"2011","unstructured":"Mishima T, Ito Y, Hosono K et al (2011) Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice. Am J Physiol Circ Physiol 300:H431\u2013H439. doi: 10.1152\/ajpheart.00466.2010","journal-title":"Am J Physiol Circ Physiol"},{"key":"807_CR69","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.athoracsur.2010.03.063","volume":"90","author":"X Zhang","year":"2010","unstructured":"Zhang X, Zhuang J, Wu H et al (2010) Inhibitory effects of Calcitonin gene-related peptides on experimental vein graft disease. Ann Thorac Surg 90:117\u2013123. doi: 10.1016\/j.athoracsur.2010.03.063","journal-title":"Ann Thorac Surg"},{"key":"807_CR70","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0306-4522(88)90018-8","volume":"25","author":"PK Mulderry","year":"1988","unstructured":"Mulderry PK, M A G, R a S et al (1988) Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience 25:195\u2013205. doi: 10.1016\/0306-4522(88)90018-8","journal-title":"Neuroscience"},{"key":"807_CR71","doi-asserted-by":"publisher","unstructured":"STERNINI C (1992) Enteric and visceral afferent CGRP neurons: targets of Innervation and differential expression patterns. Ann N Y Acad Sci 657:170\u2013186. doi: 10.1111\/j.1749-6632.1992.tb22766.x","DOI":"10.1111\/j.1749-6632.1992.tb22766.x"},{"key":"807_CR72","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0014-2999(93)90645-X","volume":"250","author":"BM Peskar","year":"1993","unstructured":"Peskar BM, Wong HC, Walsh JH, Holzer P (1993) A monoclonal antibody to calcitonin gene-related peptide abolishes capsaicin-induced gastroprotection. Eur J Pharmacol 250:201\u2013203. doi: 10.1016\/0014-2999(93)90645-X","journal-title":"Eur J Pharmacol"},{"key":"807_CR73","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0022-3565(24)37636-0","volume":"286","author":"M Reinshagen","year":"1998","unstructured":"Reinshagen M, Fl\u00e4mig G, Ernst S et al (1998) Calcitonin gene-related peptide mediates the protective effect of sensory nerves in a model of colonic injury. J Pharmacol Exp Ther 286:657\u2013661","journal-title":"J Pharmacol Exp Ther"},{"key":"807_CR74","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0143-4179(93)90051-B","volume":"25","author":"L Bartho","year":"1993","unstructured":"Bartho L, Koczan G, Maggi CA (1993) Studies on the mechanism of the contractile action of rat calcitonin gene-related peptide and of capsaicin on the guinea-pig lleum: effect of hCGRP (8-37) and CGRP tachyphylaxis. Neuropeptides 25:325\u2013329. doi: 10.1016\/0143-4179(93)90051-B","journal-title":"Neuropeptides"},{"key":"807_CR75","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2007.10.001","volume":"134","author":"T Ohno","year":"2008","unstructured":"Ohno T, Hattori Y, Komine R et al (2008) Roles of Calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis. Gastroenterology 134:215\u2013225. doi: 10.1053\/j.gastro.2007.10.001","journal-title":"Gastroenterology"},{"key":"807_CR76","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1093\/brain\/aww096","volume":"139","author":"CJ Schankin","year":"2016","unstructured":"Schankin CJ, Maniyar FH, Seo Y et al (2016) Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain 139:1994\u20132001. doi: 10.1093\/brain\/aww096","journal-title":"Brain"},{"key":"807_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/brain\/awx089","volume":"140","author":"A Hougaard","year":"2017","unstructured":"Hougaard A, Amin FM, Christensen CE et al (2017) Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain 140:1\u201310. doi: 10.1093\/brain\/awx089","journal-title":"Brain"},{"key":"807_CR78","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.brainres.2014.11.031","volume":"1600","author":"S Eftekhari","year":"2015","unstructured":"Eftekhari S, Salvatore CA, Johansson S et al (2015) Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res 1600:93\u2013109. doi: 10.1016\/j.brainres.2014.11.031","journal-title":"Brain Res"},{"key":"807_CR79","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/0306-4522(93)90270-P","volume":"54","author":"SJ Wimalawansa","year":"1993","unstructured":"Wimalawansa SJ, El-Kholy AA (1993) Comparitive study of distribution and biochemical characterization of brain calcitonin gene-related peptide receptors in five different species. Neuroscience 54:513\u2013519","journal-title":"Neuroscience"},{"key":"807_CR80","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/WCO.0000000000000438","volume":"30","author":"DD Mitsikostas","year":"2017","unstructured":"Mitsikostas DD, Reuter U (2017) Calcitonin gene-related peptide monoclonal antibodies for migraine prevention\u00a0: comparisons across randomized controlled studies. Curr Opin Neurol 30:272\u2013280. doi: 10.1097\/WCO.0000000000000438","journal-title":"Curr Opin Neurol"},{"key":"807_CR81","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478\u2013488. doi: 10.1177\/0333102414547138","journal-title":"Cephalalgia"},{"key":"807_CR82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22\u201333","journal-title":"J Manag Care Pharm"},{"key":"807_CR83","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-pharmtox-010510-100510","volume":"51","author":"H Zhou","year":"2011","unstructured":"Zhou H, Mascelli MA (2011) Mechanisms of monoclonal antibody\u2013drug interactions. Annu Rev Pharmacol Toxicol 51:359\u2013372. doi: 10.1146\/annurev-pharmtox-010510-100510","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"807_CR84","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1095\/biolreprod.102.007682","volume":"67","author":"PRR Gangula","year":"2002","unstructured":"Gangula PRR, Wimalawansa SJ, Yallampalli C (2002) Sex steroid hormones enhance Hypotensive effects of Calcitonin gene-related peptide in aged female rats. Biol Reprod 67:1881\u20131887. doi: 10.1095\/biolreprod.102.007682","journal-title":"Biol Reprod"},{"key":"807_CR85","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/acn3.197","volume":"2","author":"CS Walker","year":"2015","unstructured":"Walker CS, Eftekhari S, Bower RL et al (2015) A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol 2:595\u2013608. doi: 10.1002\/acn3.197","journal-title":"Ann Clin Transl Neurol"},{"key":"807_CR86","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/acn3.286","volume":"3","author":"KA Haanes","year":"2016","unstructured":"Haanes KA, Chan KY, MaassenVanDenBrink A (2016) Comment on \u201ca second trigeminal CGRP receptor: function and expression of the AMY1 receptor.\u201d. Ann Clin Transl Neurol 3:307\u2013308. doi: 10.1002\/acn3.286","journal-title":"Ann Clin Transl Neurol"},{"key":"807_CR87","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2147\/NDT.S33769","volume":"9","author":"E Estemalik","year":"2013","unstructured":"Estemalik E, Tepper S (2013) Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat 9:709\u2013720. doi: 10.2147\/NDT.S33769","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-017-0807-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-017-0807-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-017-0807-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T17:57:39Z","timestamp":1750874259000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-017-0807-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1186\/s10194-017-0807-1","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]},"article-number":"96"}}